Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crinetics Pharmaceuticals, Inc. - Common Stock (NQ: CRNX )

38.76 +1.41 (+3.78%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crinetics Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Crinetics Pharmaceuticals Earnings Preview
Via Benzinga
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Analyst Scoreboard: 4 Ratings For Crinetics Pharmaceuticals
Via Benzinga
8 Analysts Have This to Say About Crinetics Pharmaceuticals
Via Benzinga
Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
11 Analysts Have This to Say About Crinetics Pharmaceuticals
Via Benzinga
Why Crinetics Pharmaceuticals Stock Soared This Week
A positive late-stage trial readout fueled a major rally in the drugmaker's shares. 
Via The Motley Fool
Endocrine Diseases-Focused Crinetics Pharmaceuticals Highlights Favorable Initial Findings From Mid-Stage Study
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) released initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) study of paltusotine, an oral, once-daily investigational compound... 
Via Benzinga
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END 
Via FinancialNewsMedia
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
7 Speculative Stocks Set to Explode Higher
On the search for high-risk, high-reward opportunities? Consider taking a look at these seven speculative stocks. 
Via InvestorPlace
Top 4 Health Care Stocks That Should Keep You Up At Night
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Up 83% in 5 Days, Is Crinetics Pharmaceuticals a Buy?
Despite good results in phase 3 trials, there are barriers to its drug candidate's success. 
Via The Motley Fool
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
What's Going On With Crinetics Pharmaceuticals Stock?
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) shares are trading higher Tuesday. 
Via Benzinga
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Nasdaq Rises Over 1%; Hostess Brands Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 1% on Monday. The Dow traded up 0.29% to 34,676.52 while the NASDAQ rose 1.16% to 13,920.60. The S&P... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Avantax Shares Are Trading Higher By Over 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.